Status:
COMPLETED
ET-01 in Subjects With Lateral Canthal Lines
Lead Sponsor:
Eirion Therapeutics Inc.
Conditions:
Lateral Canthal Lines
Crow's Feet
Eligibility:
All Genders
25-65 years
Phase:
PHASE2
Brief Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Detailed Description
This product is being tested for its ability to reduce lateral canthal lines, also known as Crow's Feet.
Eligibility Criteria
Inclusion
- 25 - 65 years of age
- minimal to moderate Crow's Feet wrinkles at rest
- moderate to severe Crow's Feet wrinkles on contraction
- willingness to refrain from any product affecting skin remodeling
- female subjects must be not pregnant and non-lactating-
Exclusion
- history of adverse reactions to any prior botulinum toxin treatments
- history of vaccination or non-response to any prior botulinum toxin treatments
- botulinum toxin treatment in the prior 6 months
- present or history of neuromuscular disease, eyelid ptosis, muscle weakness, paralysis, or "dry eye"
- history of peri-ocular surgery, brow lift or related procedures
- procedures affecting the lateral canthal region in the prior 12 months
- application of topical prescription medication to the treatment area
- female subjects who are pregnant or are nursing a child
Key Trial Info
Start Date :
October 25 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 14 2018
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT03326856
Start Date
October 25 2017
End Date
November 14 2018
Last Update
April 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cary Skin Care
Cary, North Carolina, United States, 27519